Notable Labs

Notable Labs Enterprise Value

The Enterprise Value (EV) of Notable Labs (NTBLQ) as of Nov 11, 2026 is -11.48 M USD. In the previous year, Enterprise Value (EV) was -20.72 M USD — a change of -44.58% (higher).

Enterprise Value

-11.48 MUSD

YoY

-44.58%

Last updated:

Enterprise Value (EV) of Notable Labs is 2023 -11.48 M USD. Enterprise Value (EV) of Notable Labs was 2022 -20.72 M USD. It decreases by -44.58% higher compared to the previous year.

The Notable Labs Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2016
-45.25 M USD
Jan 1, 2017
-54.73 M USD
Jan 1, 2018
-49.68 M USD
Jan 1, 2019
-36.05 M USD
Jan 1, 2020
-30.18 M USD
Jan 1, 2021
-53.15 M USD
Jan 1, 2022
-20.72 M USD
Jan 1, 2023
-11.48 M USD
The Notable Labs Enterprise Value history
YEAREnterprise ValueYoY
-11.48 MUSD-44.58%
-20.72 MUSD-61.02%
-53.15 MUSD+76.11%
-30.18 MUSD-16.28%
-36.05 MUSD-27.44%
-49.68 MUSD-9.23%
-54.73 MUSD+20.95%
-45.25 MUSD+21.80%
-37.15 MUSD+1.01%
-36.78 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Enterprise Value (EV) of Notable Labs is -11.48 M USD in 2023.

Enterprise Value (EV) of Notable Labs changed from -20.72 M USD to -11.48 M USD, representing a -44.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Notable Labs

All Key Metrics — Notable Labs